A Single-arm, Prospective Clinical Study on the Antitumor Activity and Safety of Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Liaoning Tumor Hospital & Institute1 site in 1 country30 target enrollmentAugust 1, 2023

ConditionsDiffuse Large B Cell Lymphoma

InterventionsZanubrutinib Rituximab Cyclophosphamide Epirubicin Vincristine Prednisone

DrugsZanubrutinib Rituximab Cyclophosphamide Epirubicin Vincristine Prednisone

Overview

Phase: Phase 2
Intervention: Zanubrutinib
Conditions: Diffuse Large B Cell Lymphoma
Sponsor: Liaoning Tumor Hospital & Institute
Enrollment: 30
Locations: 1
Primary Endpoint: Complete response rate（CRR）
Status: Not yet recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study is a prospective, open-label, single-arm phase II clinical study to evaluate the safety and efficacy of zanubrutinib plus R-CHOP (ZR-CHOP) as the first-line therapy for newly diagnosed diffuse large B-cell lymphoma patients with high-risk factors.

Registry

clinicaltrials.gov

Start Date

August 1, 2023

End Date

August 1, 2025

Last Updated

2 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Liaoning Tumor Hospital & Institute

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Histologically confirmed DLBCL patients have one of the following risk factors(including but not limited to double expression, extranodal involvement, high ki67, bulky)；
•Age ≥ 18 years old;
•At least one measurable lesion (defined as lymph node lesion ≥15mm, extra-segmental lesions ≥ 10mm);
•ECOG performance status 0-2;
•Functions of major organs meet the following conditions: Echocardiography left ventricular ejection fraction ≥50%; Creatinine clearance ≥30 ml/min; ALT and AST≤3 times the normal range；
•Hematopoietic function should meet the following conditions: Platelet count ≥50×109/L; Hemoglobin ≥ 8.0g /dL; Absolute count of neutrophil (ANC)≥1.0×109/L;
•Expected survival of ≧3 months

Exclusion Criteria

•Major surgery within 4 weeks before treatment;
•Severe organ dysfunction(including but not limited to complications of uncontrolled cardiovascular diseases, blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases);
•Patients who cannot cooperate with treatment or follow-up on time.
•Pregnant or lactating females;
•any uncontrolled active systemic infection requiring intravenous (IV) antibiotics;
•There was a history of other active malignant diseases within the 2 years prior to study entry, except for: (1) adequately treated cervical carcinoma in situ; (2) local skin basal cell carcinoma or squamous cell carcinoma; (3) previous malignant disease that is under control and has undergone local radical treatment (surgical or other forms).
•History of severe hemorrhagic disorders, such as hemophilia A, hemophilia B, von Willebrand's disease, or spontaneous bleeding requiring blood transfusion or other medical intervention
•Human immunodeficiency virus (HIV) infection or the following serological status reflecting the presence of active hepatitis B or C virus infection: a. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) are present. Patients who are HBCAB-positive, HBsAg negative, have no hepatitis b virus (HBV) DNA (\< 20 IU/mL), and agree to be monitored for HBV virus reactivation can be enrolled. Antibodies to the hepatitis C virus (HCV) are present. HCV antibody-positive patients with no HCV RNA detected could be included in the group.
•The presence of any life-threatening disease, medical condition, or organ system dysfunction that the investigator believes may affect the subject's safety or pose a risk to the study.
•The researchers think it is not suitable to participate in this experiment.

Arms & Interventions

Zanubrutinib + R-CHOP

Intervention: Zanubrutinib

Zanubrutinib + R-CHOP

Intervention: Rituximab

Zanubrutinib + R-CHOP

Intervention: Cyclophosphamide

Zanubrutinib + R-CHOP

Intervention: Epirubicin

Zanubrutinib + R-CHOP

Intervention: Vincristine

Zanubrutinib + R-CHOP

Intervention: Prednisone

Outcomes

Primary Outcomes

Complete response rate（CRR）

Time Frame: Up to approximately 2.5 years

Secondary Outcomes

Assessment of the correlation between MYD88、CD79B、NOTCH1、BCL6、NOTCH2 or other gene abnormality and efficacy.(At 2 years)
Overall survival (OS)(Up to approximately 2.5 years)
Overall response rate （ORR）(Up to approximately 2.5 years)
Progression-free Survival(PFS)(Up to approximately 2.5 years)
Duration of Response(At 2 years)
Incidence of adverse event(At 2 years)